Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8844888rdf:typepubmed:Citationlld:pubmed
pubmed-article:8844888lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:8844888lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:8844888lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:8844888lifeskim:mentionsumls-concept:C0439858lld:lifeskim
pubmed-article:8844888lifeskim:mentionsumls-concept:C0124760lld:lifeskim
pubmed-article:8844888lifeskim:mentionsumls-concept:C1511165lld:lifeskim
pubmed-article:8844888pubmed:issue1lld:pubmed
pubmed-article:8844888pubmed:dateCreated1996-12-26lld:pubmed
pubmed-article:8844888pubmed:abstractTextA fluorinated 2-nitroimidazole radiosensitizer KU-2285 was given orally to 14 patients. The daily dose ranged from 0.5 to 2.0 g and the total dose given ranged from 0.8 to 28 g/m2. Possible toxicities observed were vomiting in two patients, muscle cramping in one and multiple joint pain in one. All these complications were mild and transient and no other toxicity was observed. The peak serum concentration of KU-2285 was 25-30 micrograms/ml at the dose of 1 g/m2. The cumulative toxicity of KU-2285 appears to be relatively low and further clinical trials seem to be warranted.lld:pubmed
pubmed-article:8844888pubmed:languageenglld:pubmed
pubmed-article:8844888pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8844888pubmed:citationSubsetIMlld:pubmed
pubmed-article:8844888pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8844888pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8844888pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8844888pubmed:statusMEDLINElld:pubmed
pubmed-article:8844888pubmed:monthJullld:pubmed
pubmed-article:8844888pubmed:issn0167-8140lld:pubmed
pubmed-article:8844888pubmed:authorpubmed-author:TakahashiMMlld:pubmed
pubmed-article:8844888pubmed:authorpubmed-author:AbeMMlld:pubmed
pubmed-article:8844888pubmed:authorpubmed-author:ShibamotoYYlld:pubmed
pubmed-article:8844888pubmed:issnTypePrintlld:pubmed
pubmed-article:8844888pubmed:volume40lld:pubmed
pubmed-article:8844888pubmed:ownerNLMlld:pubmed
pubmed-article:8844888pubmed:authorsCompleteYlld:pubmed
pubmed-article:8844888pubmed:pagination55-8lld:pubmed
pubmed-article:8844888pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:meshHeadingpubmed-meshheading:8844888-...lld:pubmed
pubmed-article:8844888pubmed:year1996lld:pubmed
pubmed-article:8844888pubmed:articleTitleA phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy.lld:pubmed
pubmed-article:8844888pubmed:affiliationDepartment of Oncology, Kyoto University, Japan.lld:pubmed
pubmed-article:8844888pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8844888pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8844888pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8844888lld:pubmed